Connect More

Why It Matters

Without connected, data‑driven engagement, biopharma risks losing market share as competition intensifies and clinicians become overwhelmed by generic outreach. Implementing integrated models directly enhances access, accelerates adoption of complex therapies, and supports better patient care.

Key Takeaways

• UK HCP access drops to 25% versus EU 53%.
• Growth window shrank from 14 to 4 years.
• Five engagement models range from strategic to marketing‑centric.
• Digital pooled channels boost clinician interaction frequency.
• Integrated teams break silos, delivering mutual value.

Pulse Analysis

The biopharma landscape is undergoing a rapid transformation driven by precision medicines and increasingly niche patient populations. As therapies become more complex, the traditional door‑to‑door sales model is losing relevance, especially in markets like the UK where only a quarter of clinicians are reachable through conventional field visits. This access gap, combined with a shrinking growth horizon—from 14 years to just four—forces companies to rethink how they build relationships with healthcare professionals and demonstrate value beyond product features.

Veeva’s five‑tiered engagement framework provides a roadmap for this shift. At the top, strategic account management and account‑based selling focus on high‑value, multi‑stakeholder environments, while field‑based partnership, service‑oriented, and marketing‑centric models cater to varying market complexities. Central to each tier is the use of real‑time data and digital pooled channels—such as live chat and AI‑driven next‑best‑action recommendations—to deliver timely, personalized content. These tools not only increase interaction frequency but also ensure that outreach aligns with clinicians’ immediate needs, turning generic touchpoints into meaningful exchanges.

Adopting an integrated, customer‑centric approach yields tangible business benefits. Breaking down silos between sales, medical, and market‑access teams creates a unified voice that resonates with clinicians, fostering trust and facilitating value‑based agreements. For patients, the ripple effect is faster access to innovative therapies and more coordinated care pathways. Companies that embed connected engagement into their DNA are positioned to capture the remaining growth opportunities, sustain competitive advantage, and ultimately shape the future of healthcare delivery.